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Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, for which, to date,
no effective treatment to ameliorate the clinical manifestations is available. The long-standing view
of ALS as affecting only motor neurons has been challenged by the finding that the skeletal muscle
plays an active role in the disease pathogenesis and can be a valuable target for therapeutic strategies.
In recent years, non-coding RNAs, including microRNAs, have emerged as important molecules that
play key roles in several cellular mechanisms involved in the pathogenic mechanisms underlying
various human conditions. In this review, we summarize how the expression of some microRNAs
is dysregulated in the skeletal muscle of ALS mouse models and patients. Shedding light on the
mechanisms underlying microRNAs dysregulation in the skeletal muscle could clarify some of the
processes involved in the pathogenesis of ALS and especially identify new promising therapeutic
targets in patients.
Keywords: amyotrophic lateral sclerosis; microRNA; skeletal muscle; gene expression signature;
molecular biomarkers; molecularly targeted therapies
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, characterized by motor
neuron degeneration, followed by muscle weakness, paralysis, and death. ALS is caused by a
combination of genetic, epigenetic, and environmental risk factors and patients undergo a very variable
disease progression, with death usually occurring because of respiratory failure in 3–5 years. Over 90%
cases of ALS are sporadic, while the remaining 5–10% show a familial inheritance. More than 20 genes
have been identified whose mutations are involved in the development of the disease. Mutations
in C9orf72, SOD1, TARDBP, UBQLN2, and FUS genes are the most frequent. To date, no effective
treatment to remarkably ameliorate the clinical manifestations is available. For a long time riluzole
has remained the only treatment, offering modest survival benefit for ALS patients. Most recently,
a second drug, edaravone, has been approved by the US Food and Drug Administration. Edaravone
leads to a reduction of ALSFRS-R (ALS Functional Rating Scale Revised) score, while, to date, there are
no data indicating any longer-term effect on patients’ safety and survival [1].
The long-standing view of ALS as affecting only motor neurons has been recently challenged by
the finding that ALS is a multi-systemic disease, in which other cell types, beyond motor neurons,
such as microglia, astrocytes, muscle, and T-cells, are involved in the pathogenesis of the disease.
The pathological modifications in motor axons and nerve terminals precede motor neuron degeneration
and the onset of clinical symptoms [2–6]; this indication has led to ALS being suggested as a distal
axonopathy, whereby skeletal muscle contributes to a retrograde signaling cascade that degrades
motor neurons [4,5,7,8].
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Before the clinical onset and during the disease progression, the skeletal muscle of ALS patients
undergoes futile cycles of reinnervation and denervation, along with motor neuron degeneration [9].
When the motor neurons die, the surviving neurons, in order to compensate for the missing synapses,
reinnervate the muscle fibers, hence the skeletal muscle is reorganized by clustering fibers of the same
metabolic type, giving rise to the phenomenon of “fiber type grouping”. Ultimately, these motor units
lose their innervation and the atrophy process starts.
Muscle fibers are classified into two main metabolic types: slow-twitch (type I) and fast-twitch
(type II) based on the myosin heavy chain (MHC) expression and on the oxidative/glycolytic metabolic
pathway utilized for ATP production [10]. Slow-twitch and fast-twitch fibers are innervated by
small-caliber axons and large-caliber axons, respectively. Interestingly, the number of large-caliber
axons (innervating type II fibers) is significantly lower in the spinal cord of ALS patients and of
the SOD1G85R transgenic mouse model, than in controls, whereas the number of small-caliber
axons (innervating type I fibers) is maintained [11,12]. Indeed, selected muscles, including the
extrinsic eye muscles and the bladder detrusor muscle, are selectively spared in ALS, suggesting
that the corresponding motor neurons in charge of their innervation are relatively resistant to
neurodegeneration. Consistently with these data, in the ALS mouse model, muscles enriched in
slow-twitch fibers undergo denervation at later stages, compared with those housing higher numbers
of fast-twitch fibers [13]. These pieces of evidence suggest that, during the early stages of ALS
pathogenesis, the muscle fibers and the motor neurons innervating them closely collaborate to
counteract the skeletal muscle atrophy. Intrinsic properties of muscle cells, together with the pattern of
impulse activity imposed on the muscle fibers, play a leading role in determining fiber type composition
in the regenerating muscles, which in turn responds differently to the same stimulation pattern.
MicroRNAs are important regulators of gene expression through a post-transcriptional
mechanism, and, through the binding of a microRNA to its specific target, can promote mRNA
stabilization or degradation or can repress translation. A key factor in this regulatory mechanism is the
RNA-induced silencing complex (RISC), a cytoplasmic ribonucleoprotein complex that incorporates
the mature microRNA and uses it as a template to recognize its target transcript [14,15]. The targeting
then occurs by the complementary binding of a small region of the microRNA, usually 7 nucleotides
long, called seed sequence, and the 3′ untranslated region (UTR) of the mRNA. Unlike the regulation
of gene expression mediated by transcriptional factors, which appears to be “on or off”, microRNAs
tend to modulate the expression of target genes on a continuous trend, so they are referred to as
“fine tuners” [16]. Although the effect of a single microRNA on the expression levels of a specific
transcript may appear small, the combinatory effects of different microRNAs on a same target, or on
several targets within the same signaling pathway, could become noteworthy [17,18]. MicroRNAs are
involved in a broader range of biological processes, both physiological and pathological, and their
dysregulation is involved in several human diseases. Many microRNAs are ubiquitously expressed and
hence play pleiotropic roles, while others display tissue-specific expression and functions. In addition
to being widely proven as molecular biomarkers in many conditions, they have also been considered
as promising therapeutic targets.
Considering the involvement of skeletal muscle in ALS pathogenesis, muscle microRNAs could
be regarded as relevant players modulating the course of the disease.
The aim of this review is to summarize how specific microRNAs are altered in the skeletal muscle
of ALS mouse models and patients, and how this dysregulation could participate and interfere with
the balance between denervation/re-innervation and muscle regeneration/atrophy processes.
2. MicroRNA Signaling Network in the Skeletal Muscle
The skeletal muscle is a very adaptive tissue with remarkable regenerative capacities. After muscle
injury, satellite cells, mononucleated muscle stem cells, normally quiescent and located between the
sarcolemma and the basement membrane of muscle fibers, start to proliferate and differentiate into
myotubes to form new tissue and repair the musculature. A set of microRNAs enriched and specifically
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expressed in the skeletal muscle have been identified and designated as myomiRs: miR-1, miR-133a,
miR-133b, miR-206, miR-208a, miR-208b, miR-499, and miR-486 [19–23]. MyomiRs fully take part
in the molecular network regulating myogenesis and muscular regeneration processes by targeting
several myogenic transcription factors and controlling the progression of myogenic differentiation
(see Nie et al. [24] for a review). Also, the conversion from fast to slow fibers could be controlled by
specific myomiRs, which regulate the expression of myosin types during muscle atrophy. In particular,
miR-208b and miR-499 play redundant roles in the specification of muscle fiber identity by activating
slow-twitch and repressing fast-twitch myofiber gene programs [22].
In ALS, the activation of satellite cells at the level of the neuromuscular junction promotes tissue
regeneration and the reorganization of the muscular fibers to counteract denervation. The role
of microRNA in the control of these crucial mechanisms has been investigated, though not yet
conclusively clarified. Several studies on muscle biopsies and on in vitro primary satellite cell cultures
have been carried out to define the role of microRNAs during the denervation process, as described
below. It could hence be interesting and useful to determine if the altered expression of specific
microRNAs in the skeletal muscle of patients could contribute to the disease course and represent
a reactive mechanism to counteract muscular atrophy. If this is the case, it would be reasonable to
design and test microRNA-targeted therapies to sustain this mechanism, with the aim of promoting
muscle regeneration.
3. MicroRNAs Altered in the Skeletal Muscle of ALS Mouse Models
Williams and colleagues [25] originally investigated microRNA expression in the skeletal muscle
during ALS progression. They showed that miR-206 is dramatically upregulated in muscle tissues of
symptomatic G93A-SOD1 transgenic mice (expressing a mutant form of human SOD1 gene, in which
glycine 93 is changed to alanine) compared with controls; they also observed the downregulation of
miR-133a, miR-133b, and miR-1 and the upregulation of miR-23a and miR-23b (Table 1) [25]. In this
model, the upregulation of miR-206 coincided with the onset of neurological symptoms, since the
transcriptional activation of miR-206 was activated in response to skeletal muscle denervation by the
myogenic basic helix-loop-helix (bHLH) proteins MyoD and myogenin [25]. miR-206 mediated its
effects by suppressing muscular histone deacetylase 4 (HDAC4) protein levels. HDAC4 inhibition,
in turn, induced the expression of FGFBP1, which promoted re-innervation and regeneration within
the neuromuscular junction [25]. Moreover, the same authors demonstrated that upon denervation
miR-206 levels increased with different rates between fast and slow muscles. In particular, upon lower
limb denervation in wild-type mice, miR-206 transcript levels robustly increased in muscles that
contain predominantly fast-twitch fibers, namely, extensor digitorum longus (EDL), tibialis anterior
(TA), and gastrocnemius/plantaris (G/P). Since the soleus (SOL) contains predominantly slow-twitch
myofibers and higher levels of miR-206, in this muscle the upregulation of miR-206 was less substantial
after denervation [25]. The authors concluded that miR-206 is required for an efficient regeneration of
neuromuscular synapses after acute nerve injury, slowing down ALS progression in the G93A-SOD1
mouse model.
Toivonen and colleagues later defined, by microarray analyses, how the microRNA expression
profile was affected in vulnerable (fast, i.e., EDL) and resistant (slow, i.e., SOL) muscle types of
symptomatic G93A-SOD1 mice in comparison with wild type mice [26]. Among those microRNAs
identified as dysregulated in various age/gender/muscle groups (namely, miR-206, miR-1, miR-133a,
miR-133b, miR-145; see Table 1), miR-206 was the only one consistently altered in the skeletal
muscle during the disease pathology [26], confirming the results of Williams et al. [25]. Moreover,
they observed that miR-206 was increased in fast-twitch muscles with respect to the slow ones,
increasing its expression in the most severely affected animals. Since miR-206 was also augmented in
the circulation of symptomatic animals, as well as in a small group of ALS patients tested in this paper,
the authors defined it as a promising candidate biomarker for ALS [26].
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Table 1. Dysregulated microRNAs in amyotrophic lateral sclerosis (ALS) skeletal muscle.
MicroRNA Model Change Reference
miR-206
G93A-SOD1 mouse ↑ [25]





G93A-SOD1 mouse ↓ [25]




G93A-SOD1 mouse ↓ [25]
G93A-SOD1 mouse ↓ [26]
Human ↑ [29]
miR-1
G93A-SOD1 mouse ↓ [25]




G93A-SOD1 mouse ↑ [25]
Human ↑ [28]
miR-23b G93A-SOD1 mouse ↑ [25]
miR-145 G93A-SOD1 mouse ↓ [26]
miR-29b Human ↑ [28]




miR-26a Human ↓ [30]
miR-27a Human ↑ [29]
miR-155 Human ↑ [29]
miR-146a Human ↑ [29]
miR-221 Human ↑ [29]
↑ up-regulated microRNA in ALS compared with control samples; ↓ down-regulated microRNA in ALS compared
with control samples.
In line with these forms of evidence, Valdez and colleagues indicated miR-206 as the prevalent
microRNA regulating the repair of the neuromuscular junction following nerve injury in G93A-SOD1
mouse model [31]. In fact, by means of selective deletion of miR-206, the authors demonstrated its
unique role in stress responses at the neuromuscular junction [31].
Interestingly, both TDP-43 and FUS/TLS, mutated in familiar ALS, encode RNA-binding proteins
involved in multiple steps of RNA processing and associated with components of microRNAs
biogenesis pathway [32]. King and co-workers demonstrated that TDP-43 physically associates
with the mature forms of the miR-1/miR-206 family of microRNAs in muscle cells, but not with the
co-transcribed miR-133 [33]. TDP-43 physically prevents the interaction between miR-1 and miR-206
with the RISC complex. In the skeletal muscle, the dampening activity of these microRNAs results
in elevated levels of their protein targets (i.e., insulin-like growth factor 1 (IGF-1) and HDAC4) [33].
This experimental evidence suggested an alternative mechanism of regulation in which a selective
interaction between a mature microRNA and a protein limits the activity of mature microRNAs,
independently from their transcription or biogenesis [33].
4. MicroRNAs Expression in Skeletal Muscle of Patients
So far, few studies have investigated the role of skeletal muscle microRNAs in the regulation of
myogenesis, neuromuscular junction innervation, and fiber type switch processes in ALS patients.
Following the above discussed results obtained by Williams and collaborators [25], Bruneteau
and colleagues investigated the involvement of the miR-206/HDAC4 pathway in the compensatory
muscle reinnervation mechanism in ALS patients [27]. To assess its possible contribution to the
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prognostic variability, they analyzed a single time-point and classified patients into two groups based
on disease progression [27]. MiR-206 transcripts were significantly upregulated in deltoid muscle
specimens of ALS patients compared with control subjects, with an increased trend in long-term
survivor patients (>5 years of disease progression without requiring respiratory support or gastronomy
feeding), although the difference between this group and the group of patients with rapidly progressive
disease did not result statistically significant [27].
Russell and co-workers demonstrated that, compared with healthy controls, in addition to
miR-206, also miR-23a, miR-29b, miR-31, and miR-455 were increased in the skeletal muscle of
ALS patients (Table 1); miR-1 and miR-181 levels were elevated, but not statistically significant,
potentially due to the relative small sample size [28]. They focused particularly on miR-23a,
which was also dysregulated in the mouse model [25], and demonstrated that it repressed PGC-1α
(peroxisome proliferator-activated receptor gamma coactivator 1-alpha) translation acting on the
3′ UTR [28]. They also demonstrated that transgenic mice over-expressing miR-23a had a reduction
in PGC-1α, cytochrome-b, and COXIV (cytochrome C oxidase subunit 4) protein levels [28], proteins
involved in mitochondrial biogenesis and function, fusion, and electron transport chain activity.
Thus, these results showed that the mitochondrial dysfunction observed in the skeletal muscle of
ALS patients was associated with a reduction in PGC-1α signaling networks; also, the increase in
several microRNAs could be potentially implicated in skeletal muscle and neuromuscular junction
regeneration. The authors concluded that the therapeutic inhibition of miR-23a might be a strategy
to rescue PGC-1α activity and ameliorate skeletal muscle mitochondrial function in ALS [28].
Interestingly, miR-23a/PGC-1α can also control the muscle fiber type determination and oxidative
metabolism, being expressed preferentially in muscle enriched in type I fibers [34,35].
Later on, Jensen et colleagues [30] studied the degeneration/regeneration process in a time-course
perspective by analyzing skeletal muscle biopsies from ALS patients collected before and after a
12-week period of normal daily activities and comparing with healthy age-matched control tissues.
They demonstrated that miR-1, miR-26a, miR-133a, and miR-455 were reduced in ALS patients
compared with controls, suggesting that both proliferation and myogenic differentiation might be
altered [30] (Table 1). These microRNAs are indeed involved in the regulation of different processes
during skeletal muscle development: miR-1, for instance, is required for muscle differentiation by
acting on HDAC4 and PAX7, a transcription factor important for satellite cells’ function, while miR-133
promotes proliferation [24]. These data were consistent with those obtained in the mouse model by
Williams et al. and Taivonen et al. regarding miR-1 and miR-133a [25,26], highlighting additional
shared mechanisms between murine models and humans.
Despite the numerous data emerging from these studies, their heterogeneity somehow underlines
the difficulty in translating results from animal models; in fact, ALS is a very complex disease with a
pleiotropic molecular etiopathogenesis, and which depends upon several different species-specific
variables. In order to assess the skeletal muscle response during ALS progression, we have analyzed
in our lab the expression of selected genes and microRNAs in patients, considering the duration
and evolution of the disease [36]. The gene expression pattern was first evaluated in relation with
the disease duration in patients categorized into “slow” or “rapid” groups, showing more or less
than 4 years of disease progression, respectively. The results indicate that miR-133a, miR-29c, miR-9,
and miR-208b were significantly upregulated in the ALS slow group, whereas miR-1 and miR-208b
expression was lower in the rapid group, relative to controls [36] (Table 2). Interestingly, the expression
of miR-499, miR-29c, and miR-208b changed significantly between the two ALS groups [36] (Table 3).
The downregulation of miR-208b and miR-499 observed in the rapid versus slow progression groups
was known to be associated with fiber type switch in the skeletal muscles. We then comparatively
analyzed gene expression data in patients stratified based on disease duration at biopsy (early: less
than one year; late: more than one year). In this case, the expression of miR-206, miR-155, miR-23a,
miR-133a, miR-133b, miR-29c, and miR-9 increased only in the early stage group, compared with
controls [36] (Table 2). miR-206 and miR-9 expression levels also significantly changed between the
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early and the late groups (Table 3); interestingly, miR-206 levels inversely correlated with the time
from symptoms onset to muscle biopsy [36]. Conversely, miR-9 expression did not correlate with the
progression of the disease. These data indicated that the skeletal muscle of ALS patients activated an
early response to denervation, which decreased over time at later stages.
Table 2. Dysregulated microRNAs in specific groups of ALS patients with respect to controls.
MicroRNA Patients’ Group Reference
miR-133a
↑ in patients with a slow disease progression 1 [36]miR-29cmiR-9
miR-208b
miR-1 ↓ in patients with a rapid disease progression 2 [36]miR-208b
miR-206



























↑ up-regulated; 1 ≥4 years of duration of disease without requiring respiratory supports; ↓ down-regulated;
2 <4 years of disease progression without respiratory support or death occurring <4 years from symptoms onset;
3 less than one year from symptoms onset to muscle biopsy; 4 patients with a higher disease severity.
At the same time, Pegoraro and collaborators analyzed the expression levels of muscle-specific
microRNAs in patients and controls, taking into account disease duration and the age at onset
of symptoms [29]. Specifically, patients were divided in subgroups according to their gender
(males, females), the age at onset of symptoms (early onset: before 55 years; late onset: next 55 years),
and the duration of the disease (short duration: 0–6 months; long duration: 7–36 months). miR-1,
miR-206, miR-133a, miR-133b, miR27a, miR-155, miR-146a, and miR-221 were upregulated in the
skeletal muscle of ALS patients compared with controls, and the expression levels of these microRNAs
were higher in male patients than in female patients, except for miR-1 [29]. The levels of microRNAs
analyzed were significantly higher in early onset than late onset patients, and significantly lower,
except for miR-133b, in patients with short versus long disease duration [29] (Table 3).
Another recent study compared the expression of small RNAs in muscle tissues of ALS
patients and healthy age-matched controls by means of small RNA-Seq [37]. The authors identified
758 un-annotated and 134 annotated tags (including microRNAs, snoRNAs, and mtRNAs) differentially
expressed in the skeletal muscle of patients, and several of the dysregulated microRNAs have
previously been linked with ALS [37]. Also in this study, the patients were divided into two groups on
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the basis of disease progression, with the aim of identifying any group-specific molecular markers that
could be associated with disease severity. Among the 19 microRNAs identified in patients showing a
defined molecular signature compared with controls, only miR-133a and miR-27a were in common
with previous data [37] (Table 2).
Table 3. Dysregulated microRNAs in stratified ALS patients.
MicroRNA Patients’ Group Reference
miR-499
↑ in patients with a slow disease progression 1 compared with rapid patients 2 [36]miR-29c
miR-208b
miR-1
















Decreased during muscular atrophy process 7 [36]miR-9
↑ up-regulated; 1 ≥4 years of duration of disease without requiring respiratory supports; 2 <4 years of disease
progression without respiratory support or death occurring <4 years from symptoms onset; 3 7–36 months of
disease duration; 4 0–6 months of disease duration; 5 <55 years at onset; 6 >55 years at onset; 7 Based on Pearson’s
correlation test of microRNAs relative expression levels of ALS patients with the time from symptoms onset to
muscle biopsy.
Finally, in vitro cultures of satellite cells from ALS patients and mouse models were also analyzed
and some characteristics of these cells have been shown, as a senescent-like morphology, disturbed
differentiation, and an apparent inability to proceed through the myogenic program [36,38–40],
resulting in a decreased ability to regenerate and mature to functional myofibers. Few works have
tried to clarify if the modification of these processes was accompanied by variations in the expression
levels of selected microRNAs. A significant downregulation of miR-133, miR-206, and miR-1 was
demonstrated in vitro, during the differentiation time course of C2C12/SOD1G93A cells, a murine
myoblast cell line stably expressing SOD1-G93A mutation, compared to control C2C12 cells [41].
5. Discussion
The experimental data obtained to date indicate the reproducible alteration of specific microRNAs
(miR-206, miR-133a, miR-133b, miR-1, miR-23a, and miR-455) in the skeletal muscles of ALS patients
and in the murine model of ALS (Table 1), yet the results concerning other microRNAs, such as
miR-133a, miR-133b, miR-1, and miR-455, are sometimes contrasting and poorly reproducible.
The strongest data are those concerning miR-206. Indeed, the mechanisms leading to the increase of
miR-206 are apparently conserved in the skeletal muscle of the mouse model and in patients, and its
upregulation is a response to the denervation specific to ALS. The importance of considering the type
of muscle analyzed in each work can also be observed, as fast and slow muscles respond differently to
denervation. miR-206 expression is highly enriched in slow muscles, which are in fact more resistant
to denervation in the mouse models of ALS [42] (Figure 1).
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Figure 1. miR-206 signaling in slow and fast twitch muscles. miR-206 levels are higher in slow muscles
than in fast ones and this basal expression makes the slow-twitch muscles more resistant to denervation.
During the denervation process, typical of ALS disease, in fast-twitch muscles miR-206 levels increase
to sustain re-innervation. Acting directly on microRNAs in the skeletal muscle could be a feasible
therapeutic strategy aimed at making the muscle more resistant to denervation, increasing the responses
that promote re-innervation (figure modified from https://smart.servier.com/). The green arrows link
the different responses of slow- and fast-twitch muscles to the different miR-206 expression levels;
the orange arrows show the signaling cascade in fast-twitch muscle following denervation; ↑: increased
levels; ↓: decreased levels.
As expected, different myomiRs results are altered and plausibly implicated in the molecular
pathogenesis of ALS, though data concerning other “non-muscular” microRNAs also appear
interesting. Additional in-depth analyses may be needed to clarify the complex network of epigenetic
post-transcriptional mechanisms underlying ALS pathogenesis. This approach may highlight
additional disease-specific pathways, thus enabling a better understanding of ALS pathophysiology
and the discovery of novel biomarkers through a bottom-up approach.
It is certainly easier to obtain more reproducible data in the mouse models, since it is possible
to work on scalable numbers of replicates and samples, overcoming the limitations in size that is
inherent to the studies on patients. Muscle biopsy is unfortunately an invasive practice and the lack
of homogeneity of the samples in terms of age, course of disease, site of sampling, and muscle types
further complicates the analysis of data. Stratifying patients and analyzing the results considering
different clinical variables (Tables 2 and 3) could represent a successful strategy to evaluate the specific
mechanisms involved in the pathogenesis of ALS. In fact, microRNAs such as miR-499 and miR-208b
appear involved only when the duration of the disease is taken into account [36].
Despite the clinical and genetic heterogeneity of ALS the resulting neuromuscular phenotypes
are largely overlapping. Hence, focusing primarily on patients by taking into account all clinical
variables would be a desirable aim for future experimental studies. This approach may allow for an
improved understanding of how the human body compensates for the disease, hence suggesting and
testing novel strategies to sustain and boost these physiologic self-healing responses. In this regard,
increasing the number of patients included in study samples, by supporting and fostering collaborative
Int. J. Mol. Sci. 2018, 19, 1534 9 of 12
multicenter studies, might allow for the identification of specific molecular signatures that enable the
categorization of patients based on muscular microRNA profiles, used as reliable disease biomarkers
for prognostic purposes.
6. Conclusions
Pharmacological interventions focused on preventing or halting motor neuron degeneration in
ALS have been unsuccessful and there is an urgent need for innovative therapeutic approaches.
Given that the current chances to find a cure for ALS may be low, symptomatic treatments
such as riluzole are the only plausible therapeutic remedies. The derangement of the functional
cross-talk between neuronal and non-neuronal cells could make some therapeutic strategies ineffective.
The availability of data about key regulators of the retrograde signaling in the skeletal muscle of
ALS patients would represent a shortcut to the clinical context. There is a complex molecular
network acting in the skeletal muscle of ALS mouse models and patients, and miR-206 emerges
as an important common microRNA implicated in different processes during ALS progression.
A valuable strategy to delay ALS progression could target the muscular molecular pathways in
which the mentioned microRNAs are involved, supporting the re-innervation process, with the aim of
improving motor performance.
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Abbreviations
ALS Amyotrophic Lateral Sclerosis
SOD1 Superoxide Dismutase 1
TARDBP TAR DNA-Binding Protein
UBQLN2 Ubiquilin 2
FUS Fused in Sarcoma
ALSFRS-R ALS Functional Rating Scale Revised
MHC Myosin Heavy Chain
ATP Adenosine Triphosphate
mRNA Messenger RNA
RISC RNA-Induced Silencing Complex
UTR Untranslated Region
myomiRs Muscle Specific MicroRNAs
bHLH Basic Helix-Loop-Helix
MyoD Myogenic Differentiation
HDAC4 Histone Deacetylase 4
FGFBP1 Fibroblast Growth Factor Binding Protein 1




TDP-43 TAR DNA-Binding Protein 43
FUS/TLS FUS RNA Binding Protein
IGF-1 Insulin-like Growth Factor 1
PGC-1α Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha
3′UTR 3′ Untranslated Region
COXIV Cytochrome C Oxidase Subunit 4
PAX7 Paired Box 7
RNA-Seq RNA Sequencing
snoRNAs Small Nucleolar RNAs
mtRNAs Mitochondrial RNAs
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